#text { margin-left:0;} .sub_menu { display:none; }
Noticias
MOUNTAIN VIEW, CA -- (Marketwired) -- 05/14/15 -- Hansen Medical, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced the completion of the world's first clinical procedure with the Magellan™ 10Fr Robotic Catheter. Interventional radiologist Dr. Gerard Goh performed the procedure at The Alfred Hospital in Melbourne, Australia. Dr. Goh used the 10Fr catheter during a robot-assisted placement of an Inferior Vena Cava (IVC) Filter. The procedure was supported in partnership with Medtel Pty Limited, Hansen Medical's exclusive distribution partner for the Magellan Robotic System in Australia and New Zealand.
The Magellan 10Fr Robotic Catheter is the latest addition to the family of robotic catheters used with the Magellan Robotic System. The 10Fr catheter allows for independent, robotic control of two telescoping catheters (an outer Guide and an inner Leader catheter). The Guide catheter has a 10Fr outer diameter, and features the largest inner lumen (7Fr) in the Magellan catheter family, which enables delivery of therapeutic devices through the robotic catheter in a broader range of endovascular procedures. The Magellan 10Fr Robotic Catheter received CE Mark approval in April 2015.
"The Magellan 10Fr Robotic Catheter will enable us to expand our use of intravascular robotics in minimally-invasive, endovascular procedures," said Dr. Goh. "The larger, 7Fr inner lumen accommodates many more therapeutic devices, including stents, balloons, and in this case, an IVC filter. The device tracked well through the catheter, and we were able to benefit from the robotic precision and stability that we have experienced during previous therapy delivery with the Magellan 6Fr and 9Fr catheters."
The Magellan Robotic System is an advanced technology that drives Magellan Robotic Catheters and guide wires during minimally-invasive, endovascular procedures. Magellan is designed to offer procedural predictability, precision, and catheter stability as physicians navigate inside blood vessels and deliver therapy. Image-guided medical procedures using interventional fluoroscopy, while growing rapidly, are the leading source of occupational ionizing radiation exposure for medical personnel1. Magellan's remote workstation allows physicians to control robotic catheters and guide wires while seated away from the radiation field, which has been shown to reduce radiation exposure for the physician by as much as 95% in complex endovascular procedures2.
"Congratulations to Dr. Goh and the team at The Alfred Hospital on this milestone procedure," saidCary Vance, President and Chief Executive Officer of Hansen Medical. "We are excited that the Magellan 10Fr Robotic Catheter will enable our physician and hospital customers to expand utilization of Magellan. We believe that this will enable more patients to benefit from robotic precision and control in the minimally-invasive treatment of vascular disease."
About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedures globally. The Magellan Robotic System offers several important features including:
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is a global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, Magellan Robotic Catheters, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Company's mission is to enable Cardiac Arrhythmia and Endovascular Procedures and to improve patient outcomes through the use of Intravascular Robotics. Additional information can be found at www.hansenmedical.com.
"Hansen Medical," "Hansen Medical (with Heart Design)," and "Heart Design (Logo)" are registered trademarks, and "Magellan" and "Hansen Medical Magellan" are trademarks of Hansen Medical, Inc. in the U.S. and other countries. All other trademarks are the property of their respective owners.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and other similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements regarding the potential benefits of our robotic systems for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: factors relating to engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the rate of adoption of our systems and the rate of use of our catheters; our ability to manage expenses and cash flow, and obtain adequate financing; and other risks more fully described in the "Risk Factors" in our annual report on Form 10-K for the year endedDecember 31, 2014, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
1 U.S. Environmental Protection Agency of Radiation Protection Programs Home Page; Health Effects,http://www.epa.gov/rpdweb00/understand/health_effects.html (Accessed on November 10, 2014)
2 Robotic Catheter Assistance: The Relationship on Radiation Exposure, presentation by Barry Katzen, MD during Charing Cross International Symposium, London, April 29, 2015.
Source: Hansen Medical, Inc.